

Hans Nijman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3267568/publications.pdf>

Version: 2024-02-01

113
papers

7,632
citations

101384

36
h-index

56606

83
g-index

118
all docs

118
docs citations

118
times ranked

9926
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 390-399.	0.4	12
2	Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis – A review. <i>Cancer Treatment Reviews</i> , 2022, 102, 102311.	3.4	14
3	Topical Imiquimod Treatment of High-grade Cervical Intraepithelial Neoplasia (TOPIC-3): A Nonrandomized Multicenter Study. <i>Journal of Immunotherapy</i> , 2022, 45, 180-186.	1.2	13
4	Rapid and efficient generation of antigen-specific isogenic T cells from cryopreserved blood samples. <i>Immunology and Cell Biology</i> , 2022, 100, 285-295.	1.0	0
5	Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. <i>Nature Communications</i> , 2022, 13, 1373.	5.8	47
6	Expression of CD39 Identifies Activated Intratumoral CD8+ T Cells in Mismatch Repair Deficient Endometrial Cancer. <i>Cancers</i> , 2022, 14, 1924.	1.7	5
7	Automated causal inference in application to randomized controlled clinical trials. <i>Nature Machine Intelligence</i> , 2022, 4, 436-444.	8.3	8
8	End-of-life care for patients with advanced ovarian cancer in the Netherlands: A retrospective registry-based analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, e17612-e17612.	0.8	0
9	First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers. <i>Molecular Therapy</i> , 2021, 29, 611-625.	3.7	48
10	Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 975-986.	0.4	20
11	Tumor-infiltrating lymphocytes in the immunotherapy era. <i>Cellular and Molecular Immunology</i> , 2021, 18, 842-859.	4.8	403
12	In Vitro Systematic Drug Testing Reveals Carboplatin, Paclitaxel, and Alpelisib as a Potential Novel Combination Treatment for Adult Granulosa Cell Tumors. <i>Cancers</i> , 2021, 13, 368.	1.7	8
13	Prognostic image-based quantification of CD8CD103 T cell subsets in high-grade serous ovarian cancer patients. <i>Oncolmmunology</i> , 2021, 10, 1935104.	2.1	10
14	Combined STING levels and CD103+ T cell infiltration have significant prognostic implications for patients with cervical cancer. <i>Oncolmmunology</i> , 2021, 10, 1936391.	2.1	9
15	Frozen section diagnosis of borderline ovarian tumors with suspicious features of invasive cancer is a devil's dilemma for the surgeon: A systematic review and meta-analysis. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2021, 100, 1369-1376.	1.3	9
16	Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 768-773.	1.3	30
17	No improvement in survival of older women with cervical cancer – A nationwide study. <i>European Journal of Cancer</i> , 2021, 151, 159-167.	1.3	5
18	FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring. <i>Gynecologic Oncology</i> , 2021, 162, 413-420.	0.6	11

#	ARTICLE	IF	CITATIONS
19	482â€¦Tertiary lymphoid structures as markers of anti-tumor immunity with independent prognostic value in the PORTEC-3 trial of high-risk endometrial cancer. , 2021, , .		0
20	Borderline ovarian tumor frozen section diagnoses with features suspicious of invasive cancer: a retrospective study. Journal of Ovarian Research, 2021, 14, 139.	1.3	2
21	595â€¦Implementation of collaborative translational research (TransPORTEC) findings in an international endometrial cancer clinical trials program (RAINBO). , 2021, , .		4
22	397â€¦Molecular profiling of NSMP high-risk endometrial cancers of the PORTEC-3 trial â€œ prognostic refinement and druggable targets. , 2021, , .		6
23	Association of homozygous variants of STING1 with outcome in human cervical cancer. Cancer Science, 2021, 112, 61-71.	1.7	11
24	GMP manufacturing of Vvax001, a therapeutic anti-HPV vaccine based on recombinant viral particles. European Journal of Pharmaceutical Sciences, 2020, 143, 105096.	1.9	8
25	Therapy-Induced Changes in CXCR4 Expression in Tumor Xenografts Can Be Monitored Noninvasively with N-[11C]Methyl-AMD3465 PET. Molecular Imaging and Biology, 2020, 22, 883-890.	1.3	6
26	PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. International Journal of Gynecological Cancer, 2020, 30, 2002-2007.	1.2	135
27	Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. Clinical Cancer Research, 2020, 26, 5400-5410.	3.2	41
28	Cervical cancer with â‰¥5 mm depth of invasion and >7 mm horizontal spread â€œ Is lymph node assessment only required in patients with LVSI?. Gynecologic Oncology, 2020, 158, 282-286.	0.6	13
29	Whole Genome Analysis of Ovarian Granulosa Cell Tumors Reveals Tumor Heterogeneity and a High-Grade TP53-Specific Subgroup. Cancers, 2020, 12, 1308.	1.7	41
30	Transcriptional Activity and Stability of CD39+CD103+CD8+ T Cells in Human High-Grade Endometrial Cancer. International Journal of Molecular Sciences, 2020, 21, 3770.	1.8	13
31	Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer. Investigational New Drugs, 2020, 38, 1454-1462.	1.2	10
32	Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. Science Translational Medicine, 2020, 12, .	5.8	83
33	Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome. Oncoimmunology, 2020, 9, 1760705.	2.1	11
34	Shortâ€¦term surgical complications after radical hysterectomyâ€œA nationwide cohort study. Acta Obstetrica Et Gynecologica Scandinavica, 2020, 99, 925-932.	1.3	11
35	Survival of patients with early-stage cervical cancer after abdominal or laparoscopic radical hysterectomy: a nationwide cohort study and literature review. European Journal of Cancer, 2020, 133, 14-21.	1.3	55
36	Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer. Cancer Immunology Research, 2020, 8, 1508-1519.	1.6	45

#	ARTICLE	IF	CITATIONS
37	171â€¦Preclinical studies support therapeutic application of the leukemic cell-based cancer relapse vaccine DCP-001 in ovarian cancer. , 2020, , .		0
38	Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncology, The, 2019, 20, 1273-1285.	5.1	305
39	Localization of distant metastases defines prognosis and treatment efficacy in patients with FIGO stage IV ovarian cancer. International Journal of Gynecological Cancer, 2019, 29, 392-397.	1.2	4
40	Vaginal hysterectomy with or without bilateral salpingo-oophorectomy may be an alternative treatment for endometrial cancer patients with medical co-morbidities precluding standard surgical procedures: a systematic review. International Journal of Gynecological Cancer, 2019, 29, 299-304.	1.2	1
41	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. Cells, 2019, 8, 200.	1.8	6
42	A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer. Cancer Immunology Research, 2019, 7, 784-796.	1.6	141
43	Prognostic relevance of the molecular classification in high-risk endometrial cancer: analysis of the PORTEC-3 trial. , 2019, , .		1
44	Borderline tumours of the ovary: Common practice in the Netherlands. Gynecologic Oncology Reports, 2019, 27, 25-30.	0.3	1
45	EP824â€¦Ambiguous diagnoses of borderline ovarian tumors at frozen section with a definite diagnosis of invasive carcinoma: consequences for counseling and perioperative treatment. , 2019, , .		0
46	Whole genome sequencing of ovarian granulosa cell tumours show heterogeneity, genomic instability and tumour evolution. , 2019, , .		0
47	EP1121â€¦The clinical potential ofFOXL2c>G mutation detection in circulating tumour DNA of patients with granulosa cell tumours. , 2019, , .		1
48	Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 295-309.	5.1	426
49	Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients' probability of undergoing surgery. Gynecologic Oncology, 2018, 148, 56-61.	0.6	18
50	Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. British Journal of Cancer, 2018, 119, 1067-1074.	2.9	171
51	Changes in (risk) behavior and HPV knowledge among Dutch girls eligible for HPV vaccination: an observational cohort study. BMC Public Health, 2018, 18, 837.	1.2	6
52	L1CAM expression in uterine carcinosarcoma is limited to the epithelialâ€œmesenchymal transition. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 591-598.	1.4	9
53	Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study. Oncology, 2018, 95, 100-108.	0.9	15
54	Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative. Modern Pathology, 2018, 31, 1851-1861.	2.9	35

#	ARTICLE	IF	CITATIONS
55	Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens. <i>Oncolmmunology</i> , 2018, 7, e1487913.	2.1	36
56	Implementation of laparoscopic hysterectomy for endometrial cancer over the past decade. <i>Gynecological Surgery</i> , 2018, 15, 7.	0.9	8
57	STATEC: A randomised trial of non-selective versus selective adjuvant therapy in high risk apparent stage 1 endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS5615-TPS5615.	0.8	3
58	Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification. <i>European Journal of Cancer</i> , 2017, 78, 82-90.	1.3	6
59	Surgery for patients with newly diagnosed advanced ovarian cancer: which patient, when and extent?. <i>Current Opinion in Oncology</i> , 2017, 29, 351-358.	1.1	8
60	Compliance with adjuvant treatment guidelines in endometrial cancer: room for improvement in high risk patients. <i>Gynecologic Oncology</i> , 2017, 146, 380-385.	0.6	14
61	Preliminary stop of the TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC) trial. <i>BMC Cancer</i> , 2017, 17, 110.	1.1	18
62	Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies. <i>Modern Pathology</i> , 2017, 30, 459-468.	2.9	53
63	Immunological profiling of molecularly classified high-risk endometrial cancers identifies <i>POLE</i> -mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. <i>Oncolmmunology</i> , 2017, 6, e1264565.	2.1	102
64	CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. <i>Oncolmmunology</i> , 2017, 6, e1338230.	2.1	116
65	Noninvasive monitoring of cancer therapy induced activated T cells using [¹⁸ F]FB-IL-2 PET imaging. <i>Oncolmmunology</i> , 2017, 6, e1248014.	2.1	51
66	The impact of centralization of services on treatment delay in ovarian cancer: A study on process quality. <i>International Journal for Quality in Health Care</i> , 2017, 29, 810-816.	0.9	8
67	Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5502-5502.	0.8	23
68	Association of T cell responses after vaccination with HPV16 long peptides for late stage cervical cancer with prolonged survival.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5525-5525.	0.8	6
69	Correlation between strength of T-cell response against HPV16 and survival after vaccination with HPV16 long peptides in combination with chemotherapy for late-stage cervical cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 140-140.	0.8	4
70	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. <i>Oncotarget</i> , 2017, 8, 84579-84594.	0.8	23
71	Microsatellite instability derived <i>JAK1</i> frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer. <i>Oncotarget</i> , 2016, 7, 39885-39893.	0.8	29
72	CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. <i>European Journal of Cancer</i> , 2016, 60, 1-11.	1.3	125

#	ARTICLE	IF	CITATIONS
73	Improved outcomes due to changes in organization of care for patients with ovarian cancer in the Netherlands. <i>Gynecologic Oncology</i> , 2016, 141, 524-530.	0.6	27
74	Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts. <i>Clinical Cancer Research</i> , 2016, 22, 4215-4224.	3.2	535
75	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 207-216.	3.7	227
76	Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1114-1126.	5.1	135
77	TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC trial): study protocol for a randomized controlled trial. <i>BMC Cancer</i> , 2016, 16, 132.	1.1	14
78	Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response. <i>Clinical Cancer Research</i> , 2016, 22, 2342-2350.	3.2	132
79	Size matters: Survival benefit conferred by intratumoral T cells is dependent on surgical outcome, treatment sequence and T cell differentiation. <i>Oncolmmunology</i> , 2016, 5, e1122863.	2.1	2
80	Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. <i>Modern Pathology</i> , 2016, 29, 174-181.	2.9	68
81	Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 714-724.	3.2	51
82	CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCR β^+ CD8 α^+ T cells that can be targeted for cancer immunotherapy. <i>Oncotarget</i> , 2016, 7, 75130-75144.	0.8	64
83	Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival. <i>Oncotarget</i> , 2016, 7, 18573-18584.	0.8	40
84	Prognostic value and clinicopathologic characteristics of L1 cell adhesion molecule (L1CAM) in a large series of vulvar squamous cell carcinomas. <i>Oncotarget</i> , 2016, 7, 26192-26205.	0.8	5
85	Epitope Prediction Assays Combined with Validation Assays Strongly Narrows down Putative Cytotoxic T Lymphocyte Epitopes. <i>Vaccines</i> , 2015, 3, 203-220.	2.1	29
86	Tattoo Delivery of a Semliki Forest Virus-Based Vaccine Encoding Human Papillomavirus E6 and E7. <i>Vaccines</i> , 2015, 3, 221-238.	2.1	14
87	Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines. <i>Gene Therapy</i> , 2015, 22, 560-567.	2.3	17
88	POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3347-3355.	3.2	249
89	Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters. <i>British Journal of Cancer</i> , 2015, 113, 786-793.	2.9	20
90	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. <i>Modern Pathology</i> , 2015, 28, 836-844.	2.9	343

#	ARTICLE	IF	CITATIONS
91	Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. <i>Oncolmmunology</i> , 2015, 4, e989764.	2.1	95
92	Myeloid derived suppressor cells – An overview of combat strategies to increase immunotherapy efficacy. <i>Oncolmmunology</i> , 2015, 4, e954829.	2.1	219
93	Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 797-809.	0.4	96
94	CD20 ⁺ T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer. <i>Oncolmmunology</i> , 2015, 4, e999536.	2.1	17
95	A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development. <i>Oncolmmunology</i> , 2015, 4, e1029699.	2.1	23
96	Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5501-5501.	0.8	2
97	A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. <i>Oncotarget</i> , 2015, 6, 32228-32243.	0.8	58
98	Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity. <i>British Journal of Cancer</i> , 2014, 110, 1535-1544.	2.9	30
99	Alphavirus-based Vaccines Encoding Nonstructural Proteins of Hepatitis C Virus Induce Robust and Protective T-cell Responses. <i>Molecular Therapy</i> , 2014, 22, 881-890.	3.7	30
100	Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination. <i>International Journal of Cancer</i> , 2014, 134, 859-872.	2.3	38
101	Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer. <i>Oncolmmunology</i> , 2014, 3, e962397.	2.1	27
102	HPV-Specific Immunotherapy: Key Role for Immunomodulators. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 265-279.	0.9	12
103	Addition of interferon- γ to the p53 ^{SLP} vaccine results in increased production of interferon- γ in vaccinated colorectal cancer patients: A phase I/II clinical trial. <i>International Journal of Cancer</i> , 2013, 132, 1581-1591.	2.3	50
104	The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. <i>British Journal of Cancer</i> , 2011, 105, 93-103.	2.9	1,045
105	Heterologous Prime-Boost Immunizations with a Virosomal and an Alphavirus Replicon Vaccine. <i>Molecular Pharmaceutics</i> , 2011, 8, 65-77.	2.3	18
106	Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system. <i>Antiviral Therapy</i> , 2011, 16, 207-218.	0.6	16
107	Tumor-infiltrating Cytotoxic T Lymphocytes as Independent Prognostic Factor in Epithelial Ovarian Cancer With Wilms Tumor Protein 1 Overexpression. <i>Journal of Immunotherapy</i> , 2011, 34, 516-523.	1.2	25
108	From Tumor Immunosuppression to Eradication: Targeting Homing and Activity of Immune Effector Cells to Tumors. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-15.	3.3	123

#	ARTICLE	IF	CITATIONS
109	Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens. <i>Vaccine</i> , 2010, 28, 4275-4282.	1.7	10
110	Quality of Life After Pelvic Radiotherapy or Vaginal Brachytherapy for Endometrial Cancer: First Results of the Randomized PORTEC-2 Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 3547-3556.	0.8	253
111	Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. <i>Gynecologic Oncology</i> , 2009, 114, 105-110.	0.6	177
112	Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 449-459.	2.0	347
113	Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition. <i>Gene Therapy</i> , 2008, 15, 393-403.	2.3	19